DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer

Journal of Clinical Oncology

Volumn 31, Issue 26, 2013, Pages 3250-3258

  Haldrup, Christa ^a   Mundbjerg, Kamilla ^a   Vestergaard, Else Marie ^a   Lamy, Philippe ^a   Wild, Peter ^b   Schulz, Wolfgang A ^c   Arsov, Christian ^c   Visakorpi, Tapio ^d   Borre, Michael ^a   Høyer, Søren ^a   Ørntoft, Torben F ^a   Sørensen, Karina D ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AOX1 PROTEIN; APC PROTEIN; BISULFITE; C1ORF114 PROTEIN; GLUTATHIONE TRANSFERASE P1; GROWTH ARREST SPECIFIC PROTEIN 6; HAPLN3 PROTEIN; HOXD3 PROTEIN; KRUPPEL LIKE FACTOR 8; MOB3B PROTEIN; PROTEIN; ST6GALNAC3 PROTEIN; UNCLASSIFIED DRUG; ZNF660 PROTEIN; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; BIOCHEMICAL ANALYSIS; BIOCHEMICAL RECURRENCE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DENMARK; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DNA METHYLATION; FINLAND; GENE EXPRESSION; GENETIC SCREENING; GERMANY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SWITZERLAND; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; FOLLOW UP; GENETICS; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROMOTER REGION; PROSTATIC NEOPLASMS; SURVIVAL RATE; VALIDATION STUDY;

AGED; CASE-CONTROL STUDIES; COHORT STUDIES; DENMARK; DNA METHYLATION; FINLAND; FOLLOW-UP STUDIES; GERMANY; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSTATECTOMY; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SWITZERLAND; TUMOR MARKERS, BIOLOGICAL; VALIDATION STUDIES AS TOPIC;

EID: 84891530410     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.1847     Document Type: Conference Paper

References (30)

1. Sharma S, Kelly TK, Jones PA: Epigenetics in cancer. Carcinogenesis 31:27-36, 2010
2. Troyer DA, Lucia MS, de Bruïne AP, et al: Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies. Cancer Epidemiol Biomarkers Prev 18:2717-2722, 2009
3. Trock BJ, Brotzman MJ, Mangold LA, et al: Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU Int 110: 56-62, 2012
4. Weiss G, Cottrell S, Distler J, et al: DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. J Urol 181:1678-1685, 2009
5. Bañez LL, Sun L, van Leenders GJ, et al: Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol 184:149-156, 2010
6. Kron KJ, Liu L, Pethe VV, et al: DNA methylation of HOXD3 as a marker of prostate cancer progression. Lab Invest 90:1060-1067, 2010
7. Kron K, Liu L, Trudel D, et al: Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer. Clin Cancer Res 18:2896-2904, 2012
8. Liu L, Kron KJ, Pethe VV, et al: Association of tissue promoter methylation levels of APC, TGFbeta2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer 129:2454-2462, 2011
9. Cottrell S, Jung K, Kristiansen G, et al: Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. J Urol 177: 1753-1758, 2007
10. Hulf T, Sibbritt T, Wiklund ED, et al: Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer. Oncogene 32: 2891-2899, 2013
11. Olkhov-Mitsel E, Van der Kwast T, Kron KJ, et al: Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. Epigenetics 7:1037-1045, 2012
12. Heebøll S, Borre M, Ottosen PD, et al: Snail1 is over-expressed in prostate cancer. APMIS 117: 196-204, 2009
13. Mortezavi A, Hermanns T, Seifert HH, et al: KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res 17:1111-1121, 2011
14. Sørensen KD, Wild PJ, Mortezavi A, et al: Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res 15:1400-1410, 2009
15. Florl AR, Steinhoff C, Müller M, et al: Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer 91:985-994, 2004
16. Oster B, Thorsen K, Lamy P, et al: Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas. Int J Cancer 129:2855-2866, 2011
17. Hochberg Y: A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75:800-802, 1988
18. Goering W, Kloth M, Schulz WA: DNA methylation changes in prostate cancer. Methods Mol Biol 863:47-66, 2012
19. Statham AL, Robinson MD, Song JZ, et al: Bisulfite sequencing of chromatin immunoprecipitated DNA (BisChIP-seq) directly informs methylation status of histone-modified DNA. Genome Res 22:1120-1127, 2012
20. Prensner JR, Rubin MA, Wei JT, et al: Beyond PSA: The next generation of prostate cancer biomarkers. Sci Transl Med 4:127rv3, 2012
21. Mahapatra S, Klee EW, Young CY, et al: Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res 18:2882-2895, 2012
22. Kim JW, Kim ST, Turner AR, et al: Identification of new differentially methylated genes that have potential functional consequences in prostate cancer. PLoS One 7:e48455, 2012
23. Sainaghi PP, Castello L, Bergamasco L, et al: Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J Cell Physiol 204:36-44, 2005
24. Shiozawa Y, Pedersen EA, Patel LR, et al: GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia 12:116-127, 2010
25. Wang X, Zheng M, Liu G, et al: Kruppel-like factor 8 induces epithelial to mesenchymal transition and epithelial cell invasion. Cancer Res 67:7184-7193, 2007
26. Garattini E, Fratelli M, Terao M: The mammalian aldehyde oxidase gene family. Hum Genomics 4:119-130, 2009
27. Sigruener A, Buechler C, Orsó E, et al: Human aldehyde oxidase 1 interacts with ATP-binding cassette transporter-1 and modulates its activity in hepatocytes. Horm Metab Res 39:781-789, 2007
28. Shariat SF, Karakiewicz PI, Roehrborn CG, et al: An updated catalog of prostate cancer predictive tools. Cancer 113:3075-3099, 2008
29. Ware JH: The limitations of risk factors as prognostic tools. N Engl J Med 355:2615-2617, 2006
30. Janes H, Pepe MS, Gu W: Assessing the value of risk predictions by using risk stratification tables. Ann Intern Med 149:751-760, 2008